Big Phar­ma part­ners join ini­tia­tive to dri­ve eq­ui­ty and in­clu­sion in dig­i­tal tri­als

As dig­i­tal tri­als picked up steam amid the pan­dem­ic, some said the tech­nol­o­gy could al­so be used to ad­dress bio­phar­ma’s his­toric lack of di­ver­si­ty in the clin­ic. But if im­ple­ment­ed the wrong way, it could al­so ex­ac­er­bate the prob­lem, the Dig­i­tal Med­i­cine So­ci­ety (DiMe) warns.

That’s why DiMe is look­ing to cre­ate a frame­work and re­sources for suc­cess­ful­ly run­ning dig­i­tal tri­als. And a suite of in­dus­try play­ers — in­clud­ing Am­gen and Glax­o­SmithK­line — are join­ing the new ini­tia­tive.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER